[go: up one dir, main page]

WO2009095712A3 - 4-(3-amin0pyraz0le) pyrimidine derivatives for use as jak kinase inhibitors in the treatment of cancer - Google Patents

4-(3-amin0pyraz0le) pyrimidine derivatives for use as jak kinase inhibitors in the treatment of cancer Download PDF

Info

Publication number
WO2009095712A3
WO2009095712A3 PCT/GB2009/050074 GB2009050074W WO2009095712A3 WO 2009095712 A3 WO2009095712 A3 WO 2009095712A3 GB 2009050074 W GB2009050074 W GB 2009050074W WO 2009095712 A3 WO2009095712 A3 WO 2009095712A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
kinase inhibitors
pyrimidine derivatives
jak kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2009/050074
Other languages
French (fr)
Other versions
WO2009095712A2 (en
Inventor
Lynsie Almeida
Stephanos Ioannidis
Jeffrey Johannes
Michelle Lamb
Mei Su
Bin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2009095712A2 publication Critical patent/WO2009095712A2/en
Publication of WO2009095712A3 publication Critical patent/WO2009095712A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
PCT/GB2009/050074 2008-01-29 2009-01-26 Chemical compounds Ceased WO2009095712A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2448208P 2008-01-29 2008-01-29
US61/024,482 2008-01-29

Publications (2)

Publication Number Publication Date
WO2009095712A2 WO2009095712A2 (en) 2009-08-06
WO2009095712A3 true WO2009095712A3 (en) 2009-10-15

Family

ID=40892219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/050074 Ceased WO2009095712A2 (en) 2008-01-29 2009-01-26 Chemical compounds

Country Status (1)

Country Link
WO (1) WO2009095712A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114761013A (en) 2019-09-27 2022-07-15 迪斯克医药公司 Methods of treating myelofibrosis and related disorders
JP2023528223A (en) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド Anti-Hemoduvelin (HJV) Antibodies for Treating Myelofibrosis
CN111454214B (en) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 Synthetic method of 2-methoxy-1-pyrimidineethylamine hydrochloride

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123113A2 (en) * 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
WO2009095712A2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2012066578A3 (en) Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
MX2012002876A (en) Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof.
WO2009132202A3 (en) Macrocyclic compounds and their use as kinase inhibitors
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
MX2009009590A (en) Aminopyrimidines useful as inhibitors of protein kinases.
MX2010003668A (en) Pyrimidine substituted purine derivatives.
WO2009016410A3 (en) Chemical compounds 831
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
EA201000090A1 (en) Triple substituted derivatives of pyrimidine for the treatment of proliferative diseases
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
MX336051B (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
WO2010021918A8 (en) Compounds as kinase inhibitors
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09706007

Country of ref document: EP

Kind code of ref document: A2